4
7
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1631 |
Competence-Stimulating Peptide-12261
|
||
Competence-Stimulating Peptide-12261, a sixteen peptide, is a fragment of competence-stimulating peptide. | |||
T38559 |
Competence-Stimulating Peptide-2 (CSP-2)
|
||
Competence-Stimulating Peptide-2 (CSP-2) is a quorum sensing signal peptide synthesized by Streptococcus pneumoniae. ComD2, a compatible receptor of CSP-2, exhibits an EC 50 value of 50.7 nM. | |||
TP1631L |
Competence-Stimulating Peptide-12261 acetate
Competence-Stimulating Peptide-12261 acetate (1235882-91-3 free base) |
Others | Others |
Competence-Stimulating Peptide-12261 acetate (1235882-91-3 free base) 是感觉刺激肽的片段,是一种抑制胚管 (GT) 形成的群体感应分子。 | |||
T39175 |
CSP1
|
||
CSP1 is a highly potent and selective agonist of the ComD1 receptor, exhibiting an IC50 value of 10.3 nM. It represents a major variant of competence-stimulating peptide (CSP) and plays a crucial role in regulating the genetic transformation of S. pneumoniae through modulation of quorum sensing (QS). Additionally, CSP1 possesses antibacterial activity, further enhancing its potential as an effective antibacterial agent. |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-03588 |
ComC Protein, S. mitis, Recombinant (His & KSI)
comC,CSP,Competence-stimulating peptid... |
Streptococcus mitis | E. coli |
Acts as a pheromone, induces cells to develop competence for genetic transformation. ComC Protein, S. mitis, Recombinant (His & KSI) is expressed in E. coli expression system with N-6xHis-KSI tag. The predicted molecular weight is 17.3 kDa and the accession number is O33666. | |||
TMPK-01501 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)
MHC,Hepatitis B virus,HBV |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01491 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HBV,Hepatitis B virus |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01505 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi), Biotinylated
E7,MHC,HPV16 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01492 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi)
Hepatitis B virus,HBV,MHC |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01504 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Human, MHC (His & Avi)
MHC,HPV16,E7 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01506 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi)
HPV16,E7,MHC |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. |